Kidney transplant recipients with the interleukin-6 (IL-6) GGG/GGG promoter −597/−572/−174genotype were shown to have a better long-term outcome. Further, the same −597/−572/−174genotype was found to be associated with less IL-6 production in healthy control subjects. To verify this observation in potential kidney transplant recipients, IL-6 production was analyzed in 85/142 hemodialysis patients. We could not confirm an impaired IL-6 secretion in carriers of the GGG/GGG −597/−572/−174genotype and propose a significantly lower IL-6 production in hemodialysis patients versus healthy control subjects to explain this. However, we suggest subsequent studies of IL-6 production in kidney allograft recipients to further elucidate the pathophysiological relevance of IL-6 for transplant outcome.
Get full access to this article
View all access options for this article.
References
1.
AgrawalS, GollapudiP, ElahimehrR, PahlMV, VaziriND. 2010. Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. Nephrol Dial Transplant, 25,3:737–746.
2.
BreulmannB, BantisC, SiekierkaM, BlumeC, AkerS, KuhrN, GrabenseeB, IvensK. 2007. Influence of cytokine genes polymorphisms on long-term outcome in renal transplantation. Clin Transplant, 21,5:615–621.
3.
FishmanD, FauldsG, JefferyR, Mohamed-AliV, YudkinJS, HumphriesS, WooP. 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest, 102,7:1369–1376.
4.
GadelhaSR, Junior AlcantaraLC, CostaGC, AcostaAX, RiosD, KashimaS, CovasDT, Galvao-CastroB. 2008. Correlation between polymorphisms at interleukin-6 but not at interleukin-10 promoter and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Brazilian individuals. J Med Virol, 80,12:2141–2146.
5.
GirndtM, HeineGH, KohlerH. 2006. Gene polymorphism association studies in dialysis: anemia and host immunity. Semin Dial, 19,3:227–231.
6.
HärtelC, IblherP, PuzikA, WortmeierK, EbelB, SchultzC, Müller-SteinhardtM. 2006. Immunosuppressive activity of the immunophilin-binding drug Sanglifehrin A in human whole blood: potent inhibition of interleukin-6 produced by lymphocytes and monocytes. Scand J Immunol, 63,1:26–34.
7.
HeJQ, ForemanMG, ShumanskyK, ZhangX, AkhabirL, SinDD, ManSF, DemeoDL, LitonjuaAA, SilvermanE, ConnettJE, AnthonisenNR, WiseR, PareP, SandfordAJ. 2009. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax, 64,8:698–704.
8.
KrugerB, WalbererA, FarkasS, TokmakF, ObedA, SchenkerP, HenningB, SchlittHJ, KramerBK, BanasB. 2009. The impact of “high-producer” interleukin-6 haplotypes on cardiovascular morbidity and mortality in a kidney transplant population. Transplant Proc, 41,6:2539–2543.
9.
MalaponteG, BevelacquaV, FatuzzoP, RapisardaF, EmmanueleG, TravaliS, MazzarinoMC. 2002. IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrol Dial Transplant, 17,11:1964–1970.
10.
MarshallSE, McLarenAJ, McKinneyEF, BirdTG, HaldarNA, BunceM, MorrisPJ, WelshKI. 2001. Donor cytokine genotype influences the development of acute rejection after renal transplantation. Transplantation, 71,3:469–476.
11.
Müller-SteinhardtM, EbelB, HärtelC. 2007. The impact of interleukin-6 promoter -597/-572/-174genotype on interleukin-6 production after lipopolysaccharide stimulation. Clin Exp Immunol, 147,2:339–345.
12.
Müller-SteinhardtM, FrickeL, MüllerB, EbelB, KirchnerH, HärtelC. 2004. Cooperative influence of the interleukin-6 promoter polymorphisms -597, -572 and -174 on long-term kidney allograft survival. Am J Transplant, 4,3:402–406.
13.
Müller-SteinhardtM, KockN, HärtelC, KirchnerH, SteinhoffJ. 2001. Production of monokines in patients under polysulphone haemodiafiltration is influenced by the ultrafiltration flow rate. Nephrol Dial Transplant, 16,9:1830–1837.
14.
Müller-SteinhardtM, SchulteF, KlüterH, BugertP. 2009. Optimized PCR with sequence specific primers (PCR-SSP) for fast and efficient determination of Interleukin-6 Promoter -597/-572/-174Haplotypes. BMC Res Notes, 2:245.
15.
RayA, LaForgeKS, SehgalPB. 1990. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol, 10,11:5736–5746.
TerryCF, LoukaciV, GreenFR. 2000. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem, 275,24:18138–18144.
18.
TsaiPC, ChenCJ, LaiHM, ChangSJ. 2008. Analysis of polymorphisms in the promoter region and protein levels of interleukin-6 gene among gout patients. Clin Exp Rheumatol, 26,5:841–847.
